LifeStance Health Gr Bolsa (NASDAQ: LFST)

LifeStance Health Gr (NASDAQ:LFST) Bolsa

LifeStance Health Gr

LifeStance Health Group Inc is a mental healthcare company that operates as a provider of outpatient mental health services, spanning psychiatric evaluations and treatment, psychological and neuropsychological testing, and individual, family and group therapy. The group y has a single operating and reportable segment of mental health services.

LifeStance Health Group

LifeStance Health Group, Inc. - Common Stock

LifeStance Health Group Inc

Earnings

News

Kingsway Financial Servs FY24 Sales $109.4M Up From $103.2M YoY

<p>Galiano Gold (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/GAU#AMEX">GAU</a>) reported quarterly earnings of $0.02 per share which missed the analyst consensus estimate of $0.06 by 66.67 percent. This is a 166.67 percent increase over losses of $(0.03) per share from the same period last year.  The company reported quarterly sales of $64.55 million which missed the analyst consensus estimate of $77.00 million by 16.17 percent.  This is a 8.46 percent increase over sales of $59.51 million the same period last year.</p>


Earnings Misses

Galiano Gold Q4 2024 Adj EPS $0.02 Misses $0.06 Estimate, Sales $64.55M Miss $77.00M Estimate

<p>Cenovus Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVE#NYSE">CVE</a>) has outperformed the market over the past 5 years by 31.16% on an annualized basis producing an average annual return of 51.06%. Currently, Cenovus Energy has a market capitalization of $24.87 billion. </p>
<p><strong>Buying $1000 In CVE:</strong> If an investor had bought $1000 of CVE stock 5 years ago, it would be worth <strong>$8,298.78</strong> today based on a price of $13.65 for CVE at the time of writing.</p>
<h3>Cenovus Energy's Performance Over Last 5 Years</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1742246121_0.png" alt="comp_fig" /></p>
<p>Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.</p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Trading Ideas

Here's How Much $1000 Invested In Cenovus Energy 5 Years Ago Would Be Worth Today

<h3>Gainers</h3>
<ul>
<li><strong>Sportsman's Warehouse</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPWH#NASDAQ">SPWH</a>) stock rose 6.7% to $1.12 during Monday's after-market session. The company's market cap stands at $42.5 million. </li>
<li><strong>Lovesac</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LOVE#NASDAQ">LOVE</a>) shares increased by 4.98% to $16.63. The company's market cap stands at $256.6 million. </li>
<li><strong>Holley</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HLLY#NYSE">HLLY</a>) shares moved upwards by 4.89% to $2.57. The market value of their outstanding shares is at $305.0 million. As per the press release, Q4 earnings came out 4 days ago. </li>
<li><strong>AMMO</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/POWW#NASDAQ">POWW</a>) stock rose 4.89% to $1.5. The market value of their outstanding shares is at $178.1 million. </li>
<li><strong>Cenntro</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CENN#NASDAQ">CENN</a>) shares moved upwards by 4.77% to $1.01. The company's market cap stands at $31.1 million. </li>
<li><strong>Springview Holdings</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPHL#NASDAQ">SPHL</a>) stock moved upwards by 4.39% to $0.64. The company's market cap stands at $7.3 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li><strong>Lazydays Hldgs</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GORV#NASDAQ">GORV</a>) shares decreased by 6.7% to $0.68 during Monday's after-market session. The company's market cap stands at $74.8 million. </li>
<li><strong>Mingteng International</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTEN#NASDAQ">MTEN</a>) stock declined by 5.32% to $7.3. The market value of their outstanding shares is at $49.9 million. </li>
<li><strong>Thunder Power Holdings</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIEV#NASDAQ">AIEV</a>) shares fell 5.06% to $0.17. The company's market cap stands at $8.4 million. </li>
<li><strong>Neo-Concept International</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCI#NASDAQ">NCI</a>) shares fell 4.99% to $0.39. The market value of their outstanding shares is at $7.8 million. </li>
<li><strong>Emerson Radio</strong> (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/MSN#AMEX">MSN</a>) shares declined by 4.34% to $0.42. The company's market cap stands at $8.8 million. </li>
<li><strong>Vision Marine Techs</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VMAR#NASDAQ">VMAR</a>) stock declined by 3.8% to $0.63. The company's market cap stands at $6.2 million.<br />
<strong>See Also:</strong> <a href="http://www.benzinga.com/money/best-consumer-cyclical-stocks/" title="www.benzinga.com/money/best-consumer-cyclical-stocks/">www.benzinga.com/money/best-consumer-cyclical-stocks/</a></li>
</ul>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Movers

AIEV

CENN

GORV

HLLY

LOVE

MTEN

POWW

SPHL

SPWH

VMAR

12 Consumer Discretionary Stocks Moving In Monday's After-Market Session

<h3>Gainers</h3>
<ul>
<li><strong>Harrow</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HROW#NASDAQ">HROW</a>) stock moved upwards by 15.8% to $27.0 during Monday's after-market session. The market value of their outstanding shares is at $961.5 million. The company's, Q4 earnings came out today. </li>
<li><strong>Coeptis Therapeutics</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COEP#NASDAQ">COEP</a>) shares moved upwards by 14.7% to $9.75. The company's market cap stands at $31.6 million. </li>
<li><strong>Nanobiotix</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBTX#NASDAQ">NBTX</a>) stock moved upwards by 14.37% to $3.66. The company's market cap stands at $173.5 million. </li>
<li><strong>Enzo Biochem</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ENZ#NYSE">ENZ</a>) stock increased by 8.48% to $0.51. The market value of their outstanding shares is at $26.6 million. </li>
<li><strong>Citius Oncology</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTOR#NASDAQ">CTOR</a>) stock increased by 7.93% to $0.62. The market value of their outstanding shares is at $44.1 million. </li>
<li><strong>Sensei Biotherapeutics</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNSE#NASDAQ">SNSE</a>) stock rose 6.31% to $0.47. The market value of their outstanding shares is at $11.8 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li><strong>Kyverna Therapeutics</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KYTX#NASDAQ">KYTX</a>) shares fell 20.5% to $2.02 during Monday's after-market session. The market value of their outstanding shares is at $87.1 million. </li>
<li><strong>Virpax Pharmaceuticals</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRPX#NASDAQ">VRPX</a>) stock decreased by 17.93% to $0.14. The market value of their outstanding shares is at $2.5 million. </li>
<li><strong>Hyperfine</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HYPR#NASDAQ">HYPR</a>) shares declined by 12.5% to $1.12. The company's market cap stands at $86.7 million. As per the press release, Q4 earnings came out today. </li>
<li><strong>Capstone Holding</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAPS#NASDAQ">CAPS</a>) shares declined by 9.4% to $2.7. The company's market cap stands at $3.8 million. </li>
<li><strong>Entero Therapeutics</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENTO#NASDAQ">ENTO</a>) shares decreased by 7.77% to $0.49. The market value of their outstanding shares is at $2.3 million. </li>
<li><strong>BioAtla</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCAB#NASDAQ">BCAB</a>) stock declined by 7.7% to $0.33. The company's market cap stands at $19.2 million.<br />
<strong>See Also:</strong> <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


BCAB

CAPS

COEP

CTOR

ENTO

HROW

HYPR

KYTX

NBTX

SNSE

VRPX

12 Health Care Stocks Moving In Monday's After-Market Session

<h3>Gainers</h3>
<ul>
<li><strong>Decent Holding</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXST#NASDAQ">DXST</a>) stock moved upwards by 15.5% to $1.19 during Monday's after-market session. The market value of their outstanding shares is at $19.3 million. </li>
<li><strong>SES AI</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SES#NYSE">SES</a>) shares increased by 9.5% to $0.72. The company's market cap stands at $259.7 million. </li>
<li><strong>Samfine Creation Holdings</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SFHG#NASDAQ">SFHG</a>) shares moved upwards by 7.42% to $0.76. The market value of their outstanding shares is at $16.9 million. </li>
<li><strong>Micropolis Hldgs</strong> (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/MCRP#AMEX">MCRP</a>) shares increased by 6.45% to $4.29. The company's market cap stands at $145.3 million. </li>
<li><strong>LanzaTech Global</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNZA#NASDAQ">LNZA</a>) stock increased by 4.98% to $0.51. The company's market cap stands at $100.8 million. As per the press release, Q4 earnings came out today. </li>
<li><strong>Byrna Technologies</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BYRN#NASDAQ">BYRN</a>) shares increased by 4.96% to $20.29. The company's market cap stands at $459.5 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li><strong>Energy Vault Holdings</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NRGV#NYSE">NRGV</a>) shares fell 13.2% to $0.99 during Monday's after-market session. The company's market cap stands at $150.5 million. The company's, Q4 earnings came out today. </li>
<li><strong>Callan Jmb</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CJMB#NASDAQ">CJMB</a>) stock declined by 9.55% to $5.31. The market value of their outstanding shares is at $23.5 million. </li>
<li><strong>Ocean Power Techs</strong> (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/OPTT#AMEX">OPTT</a>) shares decreased by 6.4% to $0.57. The company's market cap stands at $83.7 million. </li>
<li><strong>American Rebel Holdings</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AREB#NASDAQ">AREB</a>) shares declined by 6.4% to $0.21. </li>
<li><strong>Energous</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WATT#NASDAQ">WATT</a>) stock fell 5.75% to $0.33. The market value of their outstanding shares is at $9.9 million. </li>
<li><strong>1847 Holdings</strong> (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/EFSH#AMEX">EFSH</a>) shares declined by 5.08% to $0.13. The company's market cap stands at $3.4 million.<br />
<strong>See Also:</strong> <a href="http://www.benzinga.com/money/best-industrials-stocks/" title="www.benzinga.com/money/best-industrials-stocks/">www.benzinga.com/money/best-industrials-stocks/</a></li>
</ul>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


AREB

BYRN

CJMB

DXST

EFSH

LNZA

MCRP

NRGV

OPTT

SFHG

WATT

12 Industrials Stocks Moving In Monday's After-Market Session

<h3>Gainers</h3>
<ul>
<li><strong>Eastman Kodak</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KODK#NYSE">KODK</a>) stock increased by 13.0% to $7.89 during Monday's after-market session. The market value of their outstanding shares is at $634.3 million. The company's, Q4 earnings came out today. </li>
<li><strong>Nano Labs</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NA#NASDAQ">NA</a>) shares moved upwards by 11.37% to $5.19. The market value of their outstanding shares is at $84.8 million. </li>
<li><strong>Optical Cable</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCC#NASDAQ">OCC</a>) stock moved upwards by 11.24% to $3.66. The company's market cap stands at $30.0 million. </li>
<li><strong>Diginex</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DGNX#NASDAQ">DGNX</a>) stock increased by 6.04% to $68.04. The company's market cap stands at $1.5 billion. </li>
<li><strong>Ostin Technology Group</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OST#NASDAQ">OST</a>) stock increased by 5.29% to $1.79. The market value of their outstanding shares is at $3.3 million. </li>
<li><strong>PicoCELA</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCLA#NASDAQ">PCLA</a>) stock rose 4.99% to $0.84. The company's market cap stands at $20.7 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li><strong>X3 Holdings</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XTKG#NASDAQ">XTKG</a>) shares fell 10.5% to $0.94 during Monday's after-market session. The market value of their outstanding shares is at $1.3 million. </li>
<li><strong>AudioEye</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEYE#NASDAQ">AEYE</a>) shares decreased by 6.2% to $11.82. The market value of their outstanding shares is at $143.9 million. The company's, Q4 earnings came out 3 days ago. </li>
<li><strong>Gryphon Digital Mining</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRYP#NASDAQ">GRYP</a>) shares decreased by 5.01% to $0.21. The market value of their outstanding shares is at $14.1 million. </li>
<li><strong>Smith Micro Software</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMSI#NASDAQ">SMSI</a>) shares decreased by 4.88% to $0.78. The company's market cap stands at $13.8 million. The company's, Q4 earnings came out 4 days ago. </li>
<li><strong>ReAlpha Tech</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIRE#NASDAQ">AIRE</a>) shares decreased by 4.58% to $1.24. The company's market cap stands at $57.1 million. </li>
<li><strong>Digital Ally</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DGLY#NASDAQ">DGLY</a>) stock decreased by 4.51% to $0.07. The market value of their outstanding shares is at $1.2 million.<br />
<strong>See Also:</strong> <a href="http://www.benzinga.com/money/tech-stocks/" title="www.benzinga.com/money/tech-stocks/">www.benzinga.com/money/tech-stocks/</a></li>
</ul>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


AEYE

AIRE

DGLY

DGNX

GRYP

KODK

PCLA

SMSI

XTKG

12 Information Technology Stocks Moving In Monday's After-Market Session

<p>Altus Power (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMPS#NYSE">AMPS</a>) reported quarterly losses of $(0.38) per share which missed the analyst consensus estimate of $(0.06) by 533.33 percent. This is a 123.53 percent decrease over losses of $(0.17) per share from the same period last year.  The company reported quarterly sales of $44.47 million which missed the analyst consensus estimate of $46.64 million by 4.66 percent.  This is a 30.05 percent increase over sales of $34.19 million the same period last year.</p>


AMPS

Altus Power Q4 2024 GAAP EPS $(0.38) Misses $(0.06) Estimate, Sales $44.47M Miss $46.64M Estimate

<p>Patel will be leaving his position on Crown Castle's Board of Directors, effective March 17, 2025.</p>
<p>&nbsp;</p>


Management

Crown Castle Appointms Sunit Patel As Executive Vice President And CFO, Effective April 1, 2025

LESL

Leslie's Appoints Tony Iskander As Interim CFO And Treasurer; Scott Bowman, Who Has Served As CFO Since 2023, Has Left The Company

<p>Ratings for Host Hotels &amp; Resorts (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HST#NASDAQ">HST</a>) were provided by 5 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.</p>
<p>The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets, analyzed by analysts, offer insights with an average target of $19.0, a high estimate of $20.00, and a low estimate of $18.00. Highlighting a 9.52% decrease, the current average has fallen from the previous average price target of $21.00. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1742245257_0.png" alt="price target chart" /></p>
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
<p>A clear picture of Host Hotels &amp; Resorts's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nick Joseph</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$19.00</td>
<td>$21.00</td>
</tr>
<tr>
<td>Floris Van Dijkum</td>
<td>Compass Point</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$18.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>William Crow</td>
<td>Raymond James</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$20.00</td>
<td>$23.00</td>
</tr>
<tr>
<td>Dori Kesten</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$20.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Robin Farley</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$18.00</td>
<td>$19.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Host Hotels &amp; Resorts. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Host Hotels &amp; Resorts compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts provide insights into price targets, offering estimates for the future value of Host Hotels &amp; Resorts's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Host Hotels &amp; Resorts's market standing. Stay informed and make well-considered decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/HST/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Host Hotels &amp; Resorts analyst ratings.</strong></a></p>
<h2>Delving into Host Hotels &amp; Resorts's Background</h2>
<p>Host Hotels &amp; Resorts owns 81 predominantly urban and resort upper-upscale and luxury hotel properties representing over 43,000 rooms, mainly in the United States. Host recently sold off the company's interests in a joint venture owning a portfolio of hotels throughout Europe and also sold other joint ventures that owned properties in Asia and the United States. The majority of Host's portfolio operates under the Marriott and Starwood brands.</p>
<h3>Host Hotels &amp; Resorts: A Financial Overview</h3>
<p><strong>Market Capitalization Analysis:</strong> Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.</p>
<p><strong>Revenue Growth:</strong> Over the 3 months period, Host Hotels &amp; Resorts showcased positive performance, achieving a revenue growth rate of <strong>7.94%</strong> as of 31 December, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Real Estate sector.</p>
<p><strong>Net Margin:</strong> Host Hotels &amp; Resorts's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>7.56%</strong> net margin, the company effectively manages costs and achieves strong profitability.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of <strong>1.62%,</strong> the company showcases effective utilization of equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Host Hotels &amp; Resorts's ROA stands out, surpassing industry averages. With an impressive ROA of <strong>0.83%</strong>, the company demonstrates effective utilization of assets and strong financial performance.</p>
<p><strong>Debt Management:</strong> Host Hotels &amp; Resorts's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of <strong>0.85</strong>.</p>
<h2>The Significance of Analyst Ratings Explained</h2>
<p>Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.</p>
<p>Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Analyst Ratings

Host Hotels & Resorts Stock: A Deep Dive Into Analyst Perspectives (5 Ratings)

<p>During the last three months, 8 analysts shared their evaluations of Norwegian Cruise Line (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NCLH#NYSE">NCLH</a>), revealing diverse outlooks from bullish to bearish.</p>
<p>The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $30.12, a high estimate of $36.00, and a low estimate of $26.00. Highlighting a 1.47% decrease, the current average has fallen from the previous average price target of $30.57. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1742245250_0.png" alt="price target chart" /></p>
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
<p>The perception of Norwegian Cruise Line by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Matthew Boss</td>
<td>JP Morgan</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$30.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Ivan Feinseth</td>
<td>Tigress Financial</td>
<td>Maintains</td>
<td>Strong Buy</td>
<td>$36.00</td>
<td>$36.00</td>
</tr>
<tr>
<td>Andrew Didora</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$26.00</td>
<td>$29.00</td>
</tr>
<tr>
<td>Paul Golding</td>
<td>Macquarie</td>
<td>Raises</td>
<td>Outperform</td>
<td>$31.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>James Hardiman</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$34.00</td>
<td>$32.00</td>
</tr>
<tr>
<td>Daniel Politzer</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$28.00</td>
<td>$27.00</td>
</tr>
<tr>
<td>Laura Champine</td>
<td>Loop Capital</td>
<td>Announces</td>
<td>Hold</td>
<td>$26.00</td>
<td>-</td>
</tr>
<tr>
<td>Paul Golding</td>
<td>Macquarie</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$30.00</td>
<td>$30.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Norwegian Cruise Line. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Norwegian Cruise Line compared to the broader market.</li>
<li><strong>Price Targets:</strong> Gaining insights, analysts provide estimates for the future value of Norwegian Cruise Line's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Norwegian Cruise Line's market standing. Stay informed and make well-considered decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/NCLH/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Norwegian Cruise Line analyst ratings.</strong></a></p>
<h2>Discovering Norwegian Cruise Line: A Closer Look</h2>
<p>Norwegian Cruise Line is the world's third-largest publicly traded cruise company by berths (around 66,500). It operates 32 ships across three brands—Norwegian, Oceania, and Regent Seven Seas—offering both freestyle and luxury cruising. The company redeployed its entire fleet as of May 2022. With 13 passenger vessels on order among its brands through 2036, representing 41,000 incremental berths, Norwegian is increasing capacity faster than its peers, expanding its brand globally. Norwegian sails to around 700 global destinations.</p>
<h3>Norwegian Cruise Line: Delving into Financials</h3>
<p><strong>Market Capitalization Analysis:</strong> The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.</p>
<p><strong>Revenue Growth:</strong> Norwegian Cruise Line's remarkable performance in 3 months is evident. As of 31 December, 2024, the company achieved an impressive revenue growth rate of <strong>6.19%</strong>. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Consumer Discretionary sector.</p>
<p><strong>Net Margin:</strong> Norwegian Cruise Line's net margin excels beyond industry benchmarks, reaching <strong>12.07%</strong>. This signifies efficient cost management and strong financial health.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of <strong>19.88%,</strong> the company showcases effective utilization of equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Norwegian Cruise Line's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>1.28%</strong> ROA, the company effectively utilizes its assets for optimal returns.</p>
<p><strong>Debt Management:</strong> Norwegian Cruise Line's debt-to-equity ratio is notably higher than the industry average. With a ratio of <b>9.19</b>, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.</p>
<h2>Analyst Ratings: Simplified</h2>
<p>Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.</p>
<p>In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


NCLH

Forecasting The Future: 8 Analyst Projections For Norwegian Cruise Line

<p>During the last three months, 15 analysts shared their evaluations of NEXTracker (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXT#NASDAQ">NXT</a>), revealing diverse outlooks from bullish to bearish.</p>
<p>The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">5</td>
<td align="right">7</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">5</td>
<td align="right">5</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $56.07, a high estimate of $69.00, and a low estimate of $41.00. This upward trend is evident, with the current average reflecting a 6.88% increase from the previous average price target of $52.46.</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1742245240_0.png" alt="price target chart" /></p>
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
<p>The analysis of recent analyst actions sheds light on the perception of NEXTracker by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Christopher Dendrinos</td>
<td>RBC Capital</td>
<td>Announces</td>
<td>Outperform</td>
<td>$55.00</td>
<td>-</td>
</tr>
<tr>
<td>Julien Dumoulin-Smith</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$56.00</td>
<td>$46.00</td>
</tr>
<tr>
<td>Ameet Thakkar</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$50.00</td>
<td>$48.00</td>
</tr>
<tr>
<td>Brian Lee</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$61.00</td>
<td>$54.00</td>
</tr>
<tr>
<td>Joseph Osha</td>
<td>Guggenheim</td>
<td>Raises</td>
<td>Buy</td>
<td>$62.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Biju Perincheril</td>
<td>Susquehanna</td>
<td>Raises</td>
<td>Positive</td>
<td>$54.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Jon Windham</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$66.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>Kashy Harrison</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$50.00</td>
<td>$47.00</td>
</tr>
<tr>
<td>Jordan Levy</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$56.00</td>
<td>$54.00</td>
</tr>
<tr>
<td>Mark Strouse</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$61.00</td>
<td>$58.00</td>
</tr>
<tr>
<td>Gus Richard</td>
<td>Northland Capital Markets</td>
<td>Raises</td>
<td>Outperform</td>
<td>$55.00</td>
<td>$48.00</td>
</tr>
<tr>
<td>Christine Cho</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$60.00</td>
<td>$47.00</td>
</tr>
<tr>
<td>Praneeth Satish</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$69.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Ryan Levine</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$45.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Jeff Osborne</td>
<td>TD Cowen</td>
<td>Announces</td>
<td>Hold</td>
<td>$41.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to NEXTracker. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of NEXTracker compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts gauge the dynamics of price targets, providing estimates for the future value of NEXTracker's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into NEXTracker's market standing. Stay informed and make well-considered decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/NXT/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on NEXTracker analyst ratings.</strong></a></p>
<h2>Discovering NEXTracker: A Closer Look</h2>
<p>Nextracker (and its subsidiaries) is a leading provider of intelligent, integrated solar tracker and software solutions used in utility-scale and distributed generation solar projects around the world. Nextracker's products enable solar panels in utility-scale power plants to follow the sun's movement across the sky and optimize plant performance. Nextracker has operations in the United States, Mexico, Spain and other countries in Europe, India, Australia, the Middle East, Africa, and Brazil.</p>
<h3>A Deep Dive into NEXTracker's Financials</h3>
<p><strong>Market Capitalization Analysis:</strong> The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.</p>
<p><strong>Revenue Challenges:</strong> NEXTracker's revenue growth over 3 months faced difficulties. As of 31 December, 2024, the company experienced a decline of approximately <strong>-4.37%</strong>. This indicates a decrease in top-line earnings. When compared to others in the Industrials sector, the company faces challenges, achieving a growth rate lower than the average among peers.</p>
<p><strong>Net Margin:</strong> The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of <strong>16.97%,</strong> the company showcases strong profitability and effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> NEXTracker's ROE excels beyond industry benchmarks, reaching <strong>8.63%</strong>. This signifies robust financial management and efficient use of shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> NEXTracker's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>4.01%</strong> ROA, the company effectively utilizes its assets for optimal returns.</p>
<p><strong>Debt Management:</strong> NEXTracker's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of <strong>0.1</strong>.</p>
<h2>Analyst Ratings: Simplified</h2>
<p>Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.</p>
<p>Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


15 Analysts Have This To Say About NEXTracker

<p>Norfolk Southern (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NSC#NYSE">NSC</a>) has outperformed the market over the past 20 years by 3.56% on an annualized basis producing an average annual return of 11.76%. Currently, Norfolk Southern has a market capitalization of $53.07 billion. </p>
<p><strong>Buying $100 In NSC:</strong> If an investor had bought $100 of NSC stock 20 years ago, it would be worth <strong>$916.06</strong> today based on a price of $234.39 for NSC at the time of writing.</p>
<h3>Norfolk Southern's Performance Over Last 20 Years</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1742245232_0.png" alt="comp_fig" /></p>
<p>Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.</p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


$100 Invested In Norfolk Southern 20 Years Ago Would Be Worth This Much Today

<p>30 analysts have expressed a variety of opinions on Salesforce (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRM#NYSE">CRM</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.</p>
<p>The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">9</td>
<td align="right">11</td>
<td align="right">8</td>
<td align="right">0</td>
<td align="right">2</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">4</td>
<td align="right">7</td>
<td align="right">7</td>
<td align="right">0</td>
<td align="right">1</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
</tr>
</tbody>
</table>
<p>Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $367.7, a high estimate of $450.00, and a low estimate of $247.00. Observing a downward trend, the current average is 4.4% lower than the prior average price target of $384.63. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1742245232_0_0.png" alt="price target chart" /></p>
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
<p>In examining recent analyst actions, we gain insights into how financial experts perceive Salesforce. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Allan Verkhovski</td>
<td>Scotiabank</td>
<td>Lowers</td>
<td>Sector Outperform</td>
<td>$345.00</td>
<td>$400.00</td>
</tr>
<tr>
<td>Tyler Radke</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$335.00</td>
<td>$350.00</td>
</tr>
<tr>
<td>David Hynes</td>
<td>Canaccord Genuity</td>
<td>Lowers</td>
<td>Buy</td>
<td>$400.00</td>
<td>$415.00</td>
</tr>
<tr>
<td>Yun Kim</td>
<td>Loop Capital</td>
<td>Lowers</td>
<td>Hold</td>
<td>$300.00</td>
<td>$330.00</td>
</tr>
<tr>
<td>Gil Luria</td>
<td>DA Davidson</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$275.00</td>
<td>$300.00</td>
</tr>
<tr>
<td>Allan Verkhovski</td>
<td>Scotiabank</td>
<td>Lowers</td>
<td>Sector Outperform</td>
<td>$400.00</td>
<td>$440.00</td>
</tr>
<tr>
<td>Steve Koenig</td>
<td>Macquarie</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$320.00</td>
<td>$370.00</td>
</tr>
<tr>
<td>Keith Bachman</td>
<td>BMO Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$367.00</td>
<td>$375.00</td>
</tr>
<tr>
<td>John Difucci</td>
<td>Guggenheim</td>
<td>Maintains</td>
<td>Sell</td>
<td>$247.00</td>
<td>$247.00</td>
</tr>
<tr>
<td>Parker Lane</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Buy</td>
<td>$375.00</td>
<td>$425.00</td>
</tr>
<tr>
<td>Rob Oliver</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$400.00</td>
<td>$430.00</td>
</tr>
<tr>
<td>Brian Schwartz</td>
<td>Oppenheimer</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$380.00</td>
<td>$415.00</td>
</tr>
<tr>
<td>Scott Berg</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$400.00</td>
<td>$400.00</td>
</tr>
<tr>
<td>Brad Sills</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$400.00</td>
<td>$440.00</td>
</tr>
<tr>
<td>Brent Bracelin</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$400.00</td>
<td>$405.00</td>
</tr>
<tr>
<td>Michael Turrin</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$310.00</td>
<td>$345.00</td>
</tr>
<tr>
<td>Tyler Radke</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$350.00</td>
<td>$390.00</td>
</tr>
<tr>
<td>Patrick Walravens</td>
<td>Citizens Capital Markets</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$450.00</td>
<td>$450.00</td>
</tr>
<tr>
<td>Keith Bachman</td>
<td>BMO Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$375.00</td>
<td>$425.00</td>
</tr>
<tr>
<td>Yun Kim</td>
<td>Loop Capital</td>
<td>Lowers</td>
<td>Hold</td>
<td>$330.00</td>
<td>$360.00</td>
</tr>
<tr>
<td>Scott Berg</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$400.00</td>
<td>$400.00</td>
</tr>
<tr>
<td>Scott Berg</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$400.00</td>
<td>$400.00</td>
</tr>
<tr>
<td>J. Derrick Wood</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Buy</td>
<td>$400.00</td>
<td>$380.00</td>
</tr>
<tr>
<td>Scott Berg</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$400.00</td>
<td>$375.00</td>
</tr>
<tr>
<td>John Difucci</td>
<td>Guggenheim</td>
<td>Maintains</td>
<td>Sell</td>
<td>$247.00</td>
<td>$247.00</td>
</tr>
<tr>
<td>Steve Koenig</td>
<td>Macquarie</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$370.00</td>
<td>$370.00</td>
</tr>
<tr>
<td>Patrick Walravens</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$450.00</td>
<td>$450.00</td>
</tr>
<tr>
<td>Daniel Ives</td>
<td>Wedbush</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$425.00</td>
<td>$425.00</td>
</tr>
<tr>
<td>Scott Berg</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$375.00</td>
<td>$375.00</td>
</tr>
<tr>
<td>Brent Bracelin</td>
<td>Piper Sandler</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$405.00</td>
<td>$405.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Salesforce. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Salesforce compared to the broader market.</li>
<li><strong>Price Targets:</strong> Gaining insights, analysts provide estimates for the future value of Salesforce's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Salesforce's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/CRM/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Salesforce analyst ratings.</strong></a></p>
<h2>All You Need to Know About Salesforce</h2>
<p>Salesforce provides enterprise cloud computing solutions. The company offers customer relationship management technology that brings companies and customers together. Its Customer 360 platform helps the group to deliver a single source of truth, connecting customer data across systems, apps, and devices to help companies sell, service, market, and conduct commerce. It also offers Service Cloud for customer support, Marketing Cloud for digital marketing campaigns, Commerce Cloud as an e-commerce engine, the Salesforce Platform, which allows enterprises to build applications, and other solutions, such as MuleSoft for data integration.</p>
<h3>Financial Milestones: Salesforce's Journey</h3>
<p><strong>Market Capitalization:</strong> Boasting an elevated market capitalization, the company surpasses industry averages. This signals substantial size and strong market recognition.</p>
<p><strong>Revenue Growth:</strong> Salesforce displayed positive results in 3 months. As of 31 January, 2025, the company achieved a solid revenue growth rate of approximately <strong>7.6%</strong>. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Information Technology sector.</p>
<p><strong>Net Margin:</strong> Salesforce's net margin excels beyond industry benchmarks, reaching <strong>17.09%</strong>. This signifies efficient cost management and strong financial health.</p>
<p><strong>Return on Equity (ROE):</strong> Salesforce's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of <strong>2.85%,</strong> the company may encounter challenges in delivering satisfactory returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> Salesforce's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of <strong>1.76%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Debt Management:</strong> Salesforce's debt-to-equity ratio is below the industry average. With a ratio of <b>0.19</b>, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.</p>
<h2>Analyst Ratings: What Are They?</h2>
<p>Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.</p>
<p>In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Expert Outlook: Salesforce Through The Eyes Of 30 Analysts

<p>A $200 million expansion option remains in place. The new maturity date is March 12, 2030.</p>


Dillard's Amends And Extends $800M Senior Secured Revolving Credit Facility Consistent With Liquidity Needs

<p>In the latest quarter, 8 analysts provided ratings for Nurix Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NRIX#NASDAQ">NRIX</a>), showcasing a mix of bullish and bearish perspectives.</p>
<p>The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">3</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">3</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $27.62, along with a high estimate of $36.00 and a low estimate of $16.00. Observing a downward trend, the current average is 4.3% lower than the prior average price target of $28.86. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1742245225_0.png" alt="price target chart" /></p>
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
<p>A clear picture of Nurix Therapeutics's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Faisal Khurshid</td>
<td>Leerink Partners</td>
<td>Announces</td>
<td>Market Perform</td>
<td>$16.00</td>
<td>-</td>
</tr>
<tr>
<td>Terence Flynn</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$17.00</td>
<td>$16.00</td>
</tr>
<tr>
<td>Gregory Renza</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$27.00</td>
<td>$26.00</td>
</tr>
<tr>
<td>Eric Joseph</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$30.00</td>
<td>$31.00</td>
</tr>
<tr>
<td>Stephen Willey</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$36.00</td>
<td>$34.00</td>
</tr>
<tr>
<td>Gil Blum</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$28.00</td>
<td>$29.00</td>
</tr>
<tr>
<td>Robert Burns</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Buy</td>
<td>$36.00</td>
<td>$35.00</td>
</tr>
<tr>
<td>Sudan Loganathan</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$31.00</td>
<td>$31.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Nurix Therapeutics. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Nurix Therapeutics compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts gauge the dynamics of price targets, providing estimates for the future value of Nurix Therapeutics's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Nurix Therapeutics's market position. Stay informed and make well-informed decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/NRIX/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Nurix Therapeutics analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.</p>
<h2>Get to Know Nurix Therapeutics Better</h2>
<p>Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.</p>
<h3>Nurix Therapeutics: Delving into Financials</h3>
<p><strong>Market Capitalization:</strong> With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.</p>
<p><strong>Revenue Challenges:</strong> Nurix Therapeutics's revenue growth over 3 months faced difficulties. As of 30 November, 2024, the company experienced a decline of approximately <strong>-12.37%</strong>. This indicates a decrease in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of <strong>-440.75%,</strong> the company showcases strong profitability and effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> Nurix Therapeutics's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of <strong>-12.96%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of <strong>-9.9%,</strong> the company may need to address challenges in generating satisfactory returns from its assets.</p>
<p><strong>Debt Management:</strong> With a below-average debt-to-equity ratio of <strong>0.05</strong>, Nurix Therapeutics adopts a prudent financial strategy, indicating a balanced approach to debt management.</p>
<h2>Analyst Ratings: Simplified</h2>
<p>Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.</p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


NRIX

Beyond The Numbers: 8 Analysts Discuss Nurix Therapeutics Stock

<p>4 analysts have shared their evaluations of Academy Sports (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASO#NASDAQ">ASO</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.</p>
<p>The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets, analyzed by analysts, offer insights with an average target of $61.5, a high estimate of $65.00, and a low estimate of $60.00. This upward trend is apparent, with the current average reflecting a 3.07% increase from the previous average price target of $59.67.</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1742245214_0.png" alt="price target chart" /></p>
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
<p>An in-depth analysis of recent analyst actions unveils how financial experts perceive Academy Sports. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Paul Lejuez</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$60.00</td>
<td>$65.00</td>
</tr>
<tr>
<td>Cristina Fernandez</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$60.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>John Kernan</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Hold</td>
<td>$61.00</td>
<td>$54.00</td>
</tr>
<tr>
<td>Paul Lejuez</td>
<td>Citigroup</td>
<td>Announces</td>
<td>Buy</td>
<td>$65.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Academy Sports. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Academy Sports compared to the broader market.</li>
<li><strong>Price Targets:</strong> Delving into movements, analysts provide estimates for the future value of Academy Sports's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
<p>To gain a panoramic view of Academy Sports's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/ASO/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Academy Sports analyst ratings.</strong></a></p>
<h2>Delving into Academy Sports's Background</h2>
<p>Academy Sports and Outdoors Inc is engaged in the retail business of sporting goods and outdoor recreation products. The product categories of the company are outdoors, apparel, sports &amp; recreation, and footwear.</p>
<h3>Academy Sports: Financial Performance Dissected</h3>
<p><strong>Market Capitalization:</strong> Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.</p>
<p><strong>Revenue Growth:</strong> Academy Sports's revenue growth over a period of 3 months has faced challenges. As of 31 October, 2024, the company experienced a revenue decline of approximately <strong>-3.9%</strong>. This indicates a decrease in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Consumer Discretionary sector.</p>
<p><strong>Net Margin:</strong> The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of <strong>4.9%,</strong> the company showcases strong profitability and effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> Academy Sports's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of <strong>3.36%,</strong> the company may encounter challenges in delivering satisfactory returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> Academy Sports's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of <strong>1.32%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Debt Management:</strong> With a below-average debt-to-equity ratio of <strong>0.91</strong>, Academy Sports adopts a prudent financial strategy, indicating a balanced approach to debt management.</p>
<h2>How Are Analyst Ratings Determined?</h2>
<p>Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.</p>
<p>Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


4 Analysts Have This To Say About Academy Sports

Macro Economic Events

Politics

Global

Economics

General

In Letter To UN Security Council, Iran Rejects And Condemns 'Reckless, Provocative' Statements By Trump; Iran Says Has Not Violated Un Arms Embargo On Yemen Or Been Involved In Any Destabilizing Activities In Region; Iran Says Has Not Violated UN Arms Embargo On Yemen, Says Yemeni Authorities 'Operate Independently In Their Decision-Making And Actions

Guidance

Millrose Properties Expects Q2 EPS Of $0.65 - $0.68; Anticipates Achieving Quarterly EPS Run Rate Of $0.67 - $0.69 By Year-end 2025

Press Releases

LifeStance Reports Second Quarter 2024 Results

Legal

Bragar Eagel & Squire, P.C. Is Investigating LifeStance and Customers Bancorp and Encourages Investors to Contact the Firm

LifeStance to Present at the 22nd Annual Morgan Stanley Healthcare Conference

LifeStance Survey Finds 79% of Americans Are Experiencing Anxiety Over the 2024 U.S. Presidential Election

LifeStance to Host Third Quarter 2024 Earnings Conference Call on November 7, 2024

LifeStance Reports Third Quarter 2024 Results

Health Care

Financing

Zarminali Health Launches with $40M in Seed Funding to Transform Pediatric Care through Nationwide, Multi-specialty Practice Group

LifeStance to Host Fourth Quarter and Full Year 2024 Earnings Conference Call on February 27, 2025

LifeStance Reports Fourth Quarter and Full Year 2024 Results

LifeStance Appoints Dave Bourdon as CEO; Ken Burdick Named Executive Chairman

CUBI

LFST

Addus HomeCare Corporation - Common Stock

Addus HomeCare

Agilon Health

Amedisys

AMN Healthcare Services

Astrana Health

Aveanna Healthcare Holdings Inc. - Common Stock

Aveanna Healthcare Hldgs

BrightSpring Health Services, Inc. - Common Stock

BrightSpring Health

Chemed

Cigna Group

CorVel

CVS Health

Quest Diagnostics Incorporated Common Stock

Quest Diagnostics

DaVita

Fresenius Medical Care AG American Depositary Shares (Each representing 1/2 of an Ordinary Share)

Comments

LifeStance Health Gr

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL